These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 17065627)
1. Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe. Al-Lahham A; Appelbaum PC; van der Linden M; Reinert RR Antimicrob Agents Chemother; 2006 Nov; 50(11):3897-900. PubMed ID: 17065627 [TBL] [Abstract][Full Text] [Related]
2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. Mazzariol A; Koncan R; Vitali LA; Cornaglia G J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779 [TBL] [Abstract][Full Text] [Related]
3. Time-kill kinetics of Streptococcus pneumoniae with reduced susceptibility to telithromycin. Al-Lahham A; Reinert RR Chemotherapy; 2007; 53(3):190-3. PubMed ID: 17347565 [TBL] [Abstract][Full Text] [Related]
4. High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Wolter N; Smith AM; Low DE; Klugman KP Antimicrob Agents Chemother; 2007 Mar; 51(3):1092-5. PubMed ID: 17210764 [TBL] [Abstract][Full Text] [Related]
5. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002. Farrell DJ; Jenkins SG J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i17-22. PubMed ID: 15265832 [TBL] [Abstract][Full Text] [Related]
6. Mutational analysis of reduced telithromycin susceptibility of Streptococcus pneumoniae isolated clinically in Japan. Takaya A; Kitagawa N; Kuroe Y; Endo K; Okazaki M; Yokoyama E; Wada A; Yamamoto T FEMS Microbiol Lett; 2010 Jun; 307(1):87-93. PubMed ID: 20402783 [TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology. Kays MB; Lisek CR; Denys GA Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118 [TBL] [Abstract][Full Text] [Related]
8. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. Mazzariol A; Koncan R; Bahar G; Cornaglia G J Chemother; 2007 Oct; 19(5):500-7. PubMed ID: 18073148 [TBL] [Abstract][Full Text] [Related]
9. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Jenkins SG; Brown SD; Farrell DJ Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701 [TBL] [Abstract][Full Text] [Related]
10. Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae. Kim NJ; Park SJ; Choi SH; Lee MS; Choo EJ; Kwak YG; Woo JH; Ryu J; Jeong JY; Kim YS Microb Drug Resist; 2005; 11(3):260-5. PubMed ID: 16201929 [TBL] [Abstract][Full Text] [Related]
11. [In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study]. Gür D; Mülazimoğlu L; Unal S; Mikrobiyol Bul; 2007 Jan; 41(1):1-9. PubMed ID: 17427547 [TBL] [Abstract][Full Text] [Related]
12. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Farrell DJ; Felmingham D Antimicrob Agents Chemother; 2004 May; 48(5):1882-4. PubMed ID: 15105150 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children. Sunakawa K; Farrell DJ Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316 [TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany. Reinert RR; van der Linden M; Al-Lahham A Antimicrob Agents Chemother; 2005 Aug; 49(8):3520-2. PubMed ID: 16048973 [TBL] [Abstract][Full Text] [Related]
15. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. Jenkins SG; Farrell DJ; Patel M; Lavin BS J Infect; 2005 Dec; 51(5):355-63. PubMed ID: 15950288 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Reinert RR; Reinert S; van der Linden M; Cil MY; Al-Lahham A; Appelbaum P Antimicrob Agents Chemother; 2005 Jul; 49(7):2903-13. PubMed ID: 15980367 [TBL] [Abstract][Full Text] [Related]
17. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Jorgensen JH; Crawford SA; McElmeel ML; Whitney CG Antimicrob Agents Chemother; 2004 Feb; 48(2):605-7. PubMed ID: 14742216 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Fitoussi F; Doit C; Geslin P; Brahimi N; Bingen E Antimicrob Agents Chemother; 2001 Feb; 45(2):636-8. PubMed ID: 11158772 [TBL] [Abstract][Full Text] [Related]
19. High prevalence of the ermB gene among erythromycin-resistant streptococcus pneumoniae isolates in Germany during the winter of 2000-2001 and in vitro activity of telithromycin. Kresken M; Henrichfreise B; Bagel S; Brauers J; Wiedemann B Antimicrob Agents Chemother; 2004 Aug; 48(8):3193-5. PubMed ID: 15273149 [TBL] [Abstract][Full Text] [Related]